PT-141 (Bremelanotide)
Desire Starts in the Brain. So Does This.
What It Treats
How It Works
PT-141 activates melanocortin receptors (MC3R/MC4R) in the hypothalamus — the brain's desire center. Unlike Viagra (which works on blood vessels), PT-141 enhances actual desire and arousal at the neurological level.
Mechanism of Action
Here's why PT-141 is different from anything else on the market, and why we recommend it to both men and women. Viagra and similar medications work on blood flow — they're plumbing fixes. PT-141 works in the brain, where desire actually starts. In this illustration, you can see golden pathways lighting up deep inside the brain's hypothalamus. A 2021 review in the World Journal of Men's Health found that in a trial of 342 men who didn't respond to Viagra, PT-141 produced successful erectile response in 34% versus just 9% on placebo — because it works through a completely separate pathway in the brain. The golden lock-and-key symbols show PT-141 activating melanocortin receptors that have gone quiet due to stress, aging, or hormonal changes. The signals radiating outward represent something patients describe as "feeling like I actually want to again."
In two Phase 3 trials with over 1,200 women, bremelanotide (PT-141) significantly increased sexual desire and reduced distress related to low desire compared to placebo. Approximately 50% of treated women reported meaningful improvements in desire, leading to FDA approval for hypoactive sexual desire disorder in premenopausal women.
In a randomized trial of 342 ED patients non-responsive to sildenafil, bremelanotide (PT-141) produced successful erectile response in 34% versus 9% on placebo (p=0.03), with significantly greater intercourse satisfaction. Unlike PDE5 inhibitors which act on peripheral vasculature, bremelanotide initiates erection via hypothalamic melanocortin receptors — a completely separate pathway that explains its efficacy in men who fail conventional ED medications. The FDA approved bremelanotide (Vyleesi) in 2019, validating the melanocortin approach.
The Transformation
This comparison captures what patients experience in a way that's hard to put into words. On the left: dim, barely-connected neurons — this represents what's happening in the brain when desire fades. Many patients describe this as "I love my partner but I just don't feel anything anymore." The RECONNECT pivotal trials, published in the Journal of Sexual Medicine with over 1,200 women, found that approximately 50% reported meaningful improvements in desire — leading to FDA approval for hypoactive sexual desire disorder. On the right, after PT-141: the same neural network is alive, every connection is firing, the entire system is engaged. A follow-up study in Obstetrics & Gynecology confirmed a 38% increase in desire scores, with effects lasting up to 24 hours from a single dose.
FDA approval study demonstrated that PT-141 increased satisfying sexual events by 25% and desire scores by 38% in women with HSDD. Unlike hormonal treatments, PT-141 works within 30-60 minutes on an as-needed basis, with effects persisting up to 24 hours. The most common side effect was temporary mild nausea, which diminished with repeated use.
Ideal For
Men or women experiencing low libido, difficulty with arousal, or sexual dysfunction. Works regardless of the cause — hormonal, psychological, or age-related.
Your Protocol
Subcutaneous injection, 1-2mg taken 30-60 minutes before activity. Used on-demand, not daily. Effects last 12-72 hours.
Ready to Start PT-141 (Bremelanotide)?
Add to your plan and bundle with other services to save 15%. Or book directly.
Cancellation Policy: A $50 non-refundable deposit is required at booking for all consultations, applied toward your visit cost. We ask for at least 48 business hours' notice for cancellations or changes — one complimentary reschedule is included. No-shows or late cancellations will forfeit the deposit. By booking, you agree to these terms.
Business hours: Mon–Thu 8am–6pm · Fri 8am–12pm
